| Similar Articles |
|---|
 |
BusinessWeek
May 19, 2011
Ira Boudway |
Bid & Ask: The Deals of the Week Daimler and Rolls-Royce buy Tognum, Pratt & Whitney wins a $1 billion-plus defense contract, and a record-breaking Rolex at Christie's.   |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
The Motley Fool
May 20, 2011
Anupama Pattanaik |
Danisco and DuPont: A Delicious Duet? What chemicals and food ingredients have in common. |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
The Motley Fool
March 31, 2008
Rich Duprey |
Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment. |
The Motley Fool
April 8, 2008
Christopher Barker |
Higher Prices Going Global Rising production costs put squeeze on steel makers worldwide. |
BusinessWeek
June 16, 2011
Mider & McCracken |
M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying. |
The Motley Fool
March 19, 2009
Brian Orelli |
Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too. |
The Motley Fool
May 3, 2011
Christopher Barker |
Can Cranes Give Terex a Big Lift? The construction equipment maker aims to become a master hoister. |
The Motley Fool
August 28, 2007
Brian Orelli |
Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note. |
The Motley Fool
May 4, 2011
Brian D. Pacampara |
Varian Semiconductor Shares Skyrocketed: What You Need to Know Shares of Varian Semiconductor soared a staggering 51% on Wednesday after Applied Materials offered to buy the mobile device chip equipment specialist for $4.9 billion. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
April 7, 2010
Rick Steier |
Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity. |
The Motley Fool
February 28, 2011
Cindy Johnson |
Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries. |
The Motley Fool
January 31, 2008
Brian Orelli |
Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug. |
The Motley Fool
January 25, 2011
David Lee Smith |
DuPont Hammers the Estimates Even amid higher costs, DuPont made short work of analysts' expectations. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma. |
Chemistry World
January 11, 2011
Andrew Turley |
DuPont signs Danisco deal for $5.8 billion The deal will hit DuPont shareholders with a temporary reduction in earnings per share, but it will also take the chemical giant - which made 2009 sales of $26 billion - into an area that experts say is likely to benefit the company in the long term. |
The Motley Fool
March 5, 2008
Brian Orelli |
Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent. |
The Motley Fool
May 17, 2006
Stephen D. Simpson |
The Applied Materials Yo-Yo A consummate sentiment stock, investor attitudes about the semiconductor cycle will lift and depress Applied Materials' shares. |
The Motley Fool
November 3, 2009
Brian Orelli |
Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call. |
The Motley Fool
February 24, 2005
Stephen D. Simpson |
Happy Days for Joy Global High coal prices are leading to a revival in the mining equipment sector. |
BusinessWeek
May 12, 2011
Andrew Roberts |
Puma Is No Longer a Sneaker. It's a Lifestyle PPR is repositioning the sports-apparel maker as the Gucci of the athletic shoe market. |
The Motley Fool
January 19, 2010
Brian Orelli |
Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious. |
The Motley Fool
August 5, 2005
Stephen D. Simpson |
Can You Afford Fording? Record prices have led to exceptional payouts from this Canadian metallurgical coal trust, but what happens when prices go down? |
BusinessWeek
November 3, 2003
Diane Brady |
Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market. |
The Motley Fool
September 11, 2007
Brian Orelli |
Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix... |
The Motley Fool
February 4, 2008
Chuck Saletta |
Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker. |
Chemistry World
June 1, 2015
Phillip Broadwith |
Teva fined $1.2bn in pay-for-delay case Israeli firm Teva has reached a settlement with the US Federal Trade Commission over allegations of cutting illegal deals with generic drugmakers to stifle competition for sleep disorder drug Provigil (modafinil). |
The Motley Fool
January 16, 2008
Rich Smith |
Applied Musical Chairs, Part Deux Semiconductor equipment maker Applied Materials announces it will lay off 1,000 employees. |
The Motley Fool
April 7, 2010
Brian Orelli |
Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious. |
